Canada Meningococcal Vaccines Market Size & Outlook
Canada meningococcal vaccines market, 2018-2030 (US$M)
Related Markets
Canada meningococcal vaccines market highlights
- The Canada meningococcal vaccines market generated a revenue of USD 58.0 million in 2021 and is expected to reach USD 108.5 million by 2030.
- The Canada market is expected to grow at a CAGR of 7.2% from 2022 to 2030.
- In terms of segment, quadrivalent was the largest revenue generating type in 2021.
- Bivalent is the most lucrative type segment registering the fastest growth during the forecast period.
Meningococcal vaccines market data book summary
| Market revenue in 2021 | USD 58.0 million |
| Market revenue in 2030 | USD 108.5 million |
| Growth rate | 7.2% (CAGR from 2021 to 2030) |
| Largest segment | Quadrivalent |
| Fastest growing segment | Bivalent |
| Historical data | 2018 - 2020 |
| Base year | 2021 |
| Forecast period | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bivalent, Quadrivalent |
| Key market players worldwide | Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology |
Other key industry trends
- In terms of revenue, Canada accounted for 2.0% of the global meningococcal vaccines market in 2021.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. meningococcal vaccines market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 108.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Meningococcal Vaccines Market Scope
Meningococcal Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada meningococcal vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to meningococcal vaccines market will help companies and investors design strategic landscapes.
Quadrivalent was the largest segment with a revenue share of 64.14% in 2021. Horizon Databook has segmented the Canada meningococcal vaccines market based on bivalent, quadrivalent covering the revenue growth of each sub-segment from 2018 to 2030.
Canada is estimated to witness lucrative growth over the forecast period owing to approval and availability of new vaccines for meningitis. For instance, in October 2017, Pfizer Canada, Inc. received approval from Health Canada for Trumeau, which was made available from March 2018.
Trumeau is used for prevention from Neisseria meningitidis serogroup B bacteria for individuals aged 10 to 25. Standard immunization guidelines of meningococcal vaccine published for healthcare professionals by the government regarding available drugs & its recommended use are anticipated to drive the market.
For instance, the Government of Canada provides Canadian immunization guidelines for meningococcal vaccines. These guidelines include information on routine immunization, complete disease description, and authorized vaccines.
Reasons to subscribe to Canada meningococcal vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Canada meningococcal vaccines market databook
-
Our clientele includes a mix of meningococcal vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada meningococcal vaccines market , including forecasts for subscribers. This country databook contains high-level insights into Canada meningococcal vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Canada meningococcal vaccines market size, by type, 2018-2030 (US$M)
Canada Meningococcal Vaccines Market Outlook Share, 2021 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
